Paper Reference	Submitter name		Paper Title
O-001	Strengell	Katrin	Safety of overnight dietary treatment in LCHAD deficiency patients
O-002	Cawtherley	Sarah	Variability in dietary management in Isovaleric Acidaemia (IVA): A retrospective longitudinal cohort study
O-003	Wood	Georgina	Single-centre experience of parenteral nutrition in acutely managing methylmalonic acidaemia and propionic acidaemia
O-004	Kose	Engin	Dietary Protein Modulation, Gut Microbiota, and Metabolic Control in Methylmalonic Acidemia: A Prospective Longitudinal Study
O-009	White	Fiona	Developing a paediatric dietetic complexity tool to inform workforce requirements using a best practice model.
O-010	Syed	Mohammad Ghous	Scaling phenotypes from clinical notes to identify hidden inborn errors of metabolism using machine learning
O-013	Hejl	Ludvík	Development of a splice-switching antisense oligonucleotide for a deep-intronic ATP6AP1-CDG variant
O-019	LoPiccolo	Mary Kate	Novel ACAA2 variant causes autosomal dominant metabolic disorder with infantile hypoglycemia, steatohepatitis, lipodystrophy, lipomatosis
O-024	Kietz	Christa	Evolutionarily conserved temperature dependency leads to loss of protein O-GlcNAc in complex III deficient mice
O-026	Cappuccio	Gerarda	MECP2-Dependent LYRM4 Deficiency Leads to Multifaceted Mitochondrial Dysfunction and Derailed Neuronal Maturation
O-027	Cruz	Luisa	Tetrahydrobiopterin metabolism is a shared vulnerability in acquired and primary mitochondrial deficiencies
O-029	Rahman	Shamima	Consensus statements for diagnostic criteria and management of MELAS and stroke-like episodes
O-030	De Stefano	Lucia	Development of mRNA therapy in clinically relevant mouse models of Glycogen Storage Disease type 1b
O-031	Haijer-Schreuder	Andrea	Efficacy and nutritional changes from a phase 3 trial of DTX401 gene therapy for GSDIa
O-032	Boffa	Iolanda	Liver-Directed AAV-mediated Gene Therapy for Wolman Disease
O-033	Banikazemi	Maryam	AMT-191 gene therapy in males with Fabry disease; phase 1/2 initial safety and biomarker results
O-036	Keskinen	Timo	In vivo gene editing in a novel mouse model of argininosuccinate lyase deficiency
O-037	Banerjee	Rishi	Hepatocyte-specific gene replacement improves energy metabolism and survival in mouse model of mitochondrial CIII deficiency
O-038	von Beck	Troy	Dual mRNA lipid nanoparticles rescue metabolic performance in a mouse model of trifunctional protein deficiency
O-039	Terranova	Tatiana	Single-vector AAV8 genome editing overcomes the dominant-negative effect in mitochondrial trifunctional protein deficiency mouse
O-040	Klassa	Sven	CRISPR base editing as a one-fits-many gene editing therapy for OTC deficiency
O-041	Nassogne	Marie-Cecile	Mortality in fatty acid oxidation disorders despite newborn screening: insights from a European multicentre survey.
O-043	Mohsen	Al-Walid	N-Adipyl-D-Ala-D-His as a Superior Anaplerotic Therapy for VLCAD Deficiency in a Knockout Mouse Model
O-044	Burgenmeister	Luisa	Long-term clinical outcomes of patients with VLCAD deficiency identified by newborn screening
O-045	Juric	Viktorija	Metabolic rerouting drives odd-chain lipid enrichment in mitochondrial β-oxidation disorders
O-047	Zhang	Chen	Hydroxylated long-chain acylcarnitines cause Schwann cell bioenergetic failure: implications for LCHADD/MTPD peripheral neuropathy
O-048	Zschocke	Johannes	The Online Inherited Metabolic Diseases (OIMD) knowledgebase
O-049	Hamazaki	Takashi	Genetic diagnosis network and sustainable registry for real-world evidence in inborn errors of metabolism
O-050	Charles	Alwyn	A Multinational Study of Patient Characteristics, Management and Outcomes in Lesch-Nyhan Syndrome
O-052	McSweeney	Mel	Results from a phase 2 study evaluating the effects of GLM101 in patients with PMM2-CDG
O-053	Mistry	Pramod	Cognition and Ataxia Benefits of Venglustat in GD3: Prespecified Analyses of Neurologic Endpoints in LEAP2MONO
O-056	Murko	Simona	Newborn screening for alpha-mannosidosis: quantitative assessment of a novel biomarker in dried blood spots
O-059	Sheth	Harsh	smMIP-based genomic newborn screening in India: prospective validation against tandem mass spectrometry and whole-exome sequencing
O-061	Perrone Donnorso	Michela	A Novel Predictive Metabolomic Algorithm for Genotype-Phenotype Stratification in Newborn Screening of β-Oxidation Defects
O-072	Seyedkatouli	Najme	NADHX Repair Deficiency: From Case Reports to Multi-Omics Characterization of Systemic Metabolic and Cellular perturbations
O-078	Messina	Martina	Whole-body modelling captures biomarker changes in TYMP deficiency (MNGIE)
O-079	Johnson	Travis	An integrative orthology and model organism-based predictive framework for IMD gene discovery
O-084	Schulz	Angela	Cerliponase alfa for the treatment of CLN2 disease: Combined results from two ongoing observational studies
O-086	Cifuentes Uribe	Karla	Long-term real-world outcomes of enzyme replacement therapy in MPS I: a 10-year single-centre cohort study
O-087	Brands	Marion	CSF heparan sulfate disaccharides across the phenotypic spectrum of MPS IIIA
O-089	Peréz	Bélen	Integrated Clinical, Biochemical, and Genetic Characterization of α-Mannosidosis in a Spanish Cohort: The α-REVEAL Study
O-092	Holdorp	Julia	Long-term assessment of motor function, muscle strength and respiratory function in classic-infantile Pompe disease
O-093	Young	Amy	A single centre functional evaluation and exercise trial in Glycogen Storage Disease Type III patients
O-095	de Vreugd	Annemarie	Rehabilitation healthcare follow-up in patients with Cystinosis – outcomes and experiences
O-097	Ochoa-Ferraro	Antonio	Metabolic Pharmacist Roles Across the United Kingdom: Current Practice and Service Provision
O-099	Bertoldi	Mariarita	A tool for predict AADC deficiency from genotype: the impact of the characterized AADC variants
O-100	Tropak	Michael	Creatine Homeostasis is Controlled via Multilayered Negative Creatine Feedback Loops
O-107	Totsune	Eriko	Residual propionyl-CoA carboxylase enzymatic activity predicts responsiveness to pseudoexon-skipping antisense oligonucleotide therapy in propionic acidemia
O-109	Mekdade	Tristan	Long term Follow-up After Transplantation in Propionic Acidemia: A Retrospective French Cohort Study
O-112	Vockley	Jerry	Evaluation of CDX-6114, an Acid-Stable Oral Phenylalanine Ammonia Lyase, in a Porcine Model of PKU
O-113	van Steenis	Ellis	Which Phe is it?: Visualising the effect of lifetime Phe on neurocognition in adult PKU-patients
O-114	Verduci	Elvira	MyGut4Phe: An Italian Multicentre Pilot Study on Gut Microbiota Composition in Infants with Hyperphenylalaninaemia
O-115	Longo	Nicola	Redefining the number of true null PAH variants in phenylketonuria and sepiapterin response
O-116	Pinto	Alex	Sepiapterin Enables Liberalisation of Natural Protein Intake While Maintaining Metabolic Control in Adolescents with Phenylketonuria
O-117	Horne	Christine	Re-evaluating Sapropterin Responsiveness in PKU Using Dose Escalation Beyond 20 mg/kg/day
O-118	Giżewska	Maria	Improved efficacy with sepiapterin in participants with phenylketonuria receiving sapropterin at study screening in AMPLIPHY
O-123	Guffon-Fouilhoux	Nathalie	Extended Follow-up of DTX301: Safety and Efficacy in Adults with Late-onset Ornithine Transcarbamylase Deficiency (OTCD)
O-127	Vos	E Naomi	Developmental and transcriptional consequences of Classic Galactosemia
O-130	Kalkan Uçar	Sema	Clinical Impact of Biotin Supplementation on Glucose Homeostasis in Glycogen Storage Disease Type Ia